F
#Exelixis #Oncology #Cabozantinib
www.fool.com
Exelixis (EXEL) Q4 2025 Earnings Call Transcript
Tuesday, February 10, 2026 at 5:00 p. m. ET
Call participants
* President and Chief Executive Officer -- Michael Morrissey
* Chief Financial Officer -- Christopher Senner
* Executive Vice President, Research & Development -- Dana Aftab
* Executive Vice President, Commercial -- Patrick Joseph Haley
Need a quote from a Motley Fool analyst.
#Oncology #Healthcare #BoardOfDirectors
www.benzinga.com
The Oncology Institute Announces Addition of Board Member Mark Stolper - RadNet (NASDAQ:RDNT), Oncology Institute (NASDAQ:TOI)
CERRITOS, Calif. , Jan. 05, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI), one of the largest value-based oncology groups in the United States, today announced that Mark Stolper has joined the Board of Directors, effective January 2, 2026.
#Pharmaceuticals #Oncology #HealthcareConference
www.benzinga.com
Corbus Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference - Corbus Pharmaceuticals (NASDAQ:CRBP)
NORWOOD, Mass. , Jan. 05, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical-stage company focused on oncology and obesity, today announced that Yuval Cohen, Ph.
#ArtificialIntelligence #DrugDiscovery #Oncology
www.nasdaq.com
InSilico Signs US$888Mln Multi-Year Oncology Drug Discovery Deal With Servier
(RTTNews) - InSilico Medicine Cayman TopCo. (3696. HK), an artificial intelligence-driven drug discovery company, has announced a multi-year research and development collaboration valued at up to $888 million with France-based Servier for drug discovery and development in oncology.
#AI #Oncology #Pharmaceuticals
www.benzinga.com
Insilico Medicine Announce US$888 Million Multi-Year Collaboration with Servier for Drug Discovery and Development in Oncology
Enter your email to get Benzinga's ultimate morning update: The PreMarket Activity NewsletterInsilico Medicine achieved an R&D collaboration with Servier valued at up to US$888 million, focused on discovering and developing innovative oncology therapies, by combining Insilico's AI-driven drug discovery platforms with Servier's global expertise in cancer drug development.
